Tags

Type your tag names separated by a space and hit enter

Biomarkers of mild cognitive impairment and Alzheimer's disease.

Abstract

Alzheimer's disease (AD) is currently diagnosed only via clinical assessments and confirmed by postmortem brain pathology. Biochemical and neuroimaging markers could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and be used to monitor efficacies of disease-modifying therapies. It is now clear that cerebrospinal fluid (CSF) levels of A beta 40, A beta 42, total tau and phosphorylated tau have diagnostic values in AD. Measurements of the above CSF markers in combination are useful in predicting the risk of progression from MCI to AD. Recent advances further support a notion that plasma A beta levels, expressed as an A beta 42/A beta 40 ratio, could also be of value. New potential biomarkers are emerging, and CSF or plasma marker profiles may eventually become part of the clinician's toolkit for accurate AD diagnosis and management. These biomarkers, along with clinical assessment, neuropsychological testing and neuroimaging could achieve a much higher diagnostic accuracy for AD and related disorders in the future.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical, Drive, Singapore 117597. bchtbl@nus.edu.sg

    Source

    MeSH

    Alzheimer Disease
    Amyloid beta-Peptides
    Biomarkers
    Cognition Disorders
    Humans
    tau Proteins

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    18536828

    Citation

    Tang, Bor Luen, and Rajeev Kumar. "Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease." Annals of the Academy of Medicine, Singapore, vol. 37, no. 5, 2008, pp. 406-10.
    Tang BL, Kumar R. Biomarkers of mild cognitive impairment and Alzheimer's disease. Ann Acad Med Singap. 2008;37(5):406-10.
    Tang, B. L., & Kumar, R. (2008). Biomarkers of mild cognitive impairment and Alzheimer's disease. Annals of the Academy of Medicine, Singapore, 37(5), pp. 406-10.
    Tang BL, Kumar R. Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease. Ann Acad Med Singap. 2008;37(5):406-10. PubMed PMID: 18536828.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Biomarkers of mild cognitive impairment and Alzheimer's disease. AU - Tang,Bor Luen, AU - Kumar,Rajeev, PY - 2008/6/10/pubmed PY - 2008/12/17/medline PY - 2008/6/10/entrez SP - 406 EP - 10 JF - Annals of the Academy of Medicine, Singapore JO - Ann. Acad. Med. Singap. VL - 37 IS - 5 N2 - Alzheimer's disease (AD) is currently diagnosed only via clinical assessments and confirmed by postmortem brain pathology. Biochemical and neuroimaging markers could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and be used to monitor efficacies of disease-modifying therapies. It is now clear that cerebrospinal fluid (CSF) levels of A beta 40, A beta 42, total tau and phosphorylated tau have diagnostic values in AD. Measurements of the above CSF markers in combination are useful in predicting the risk of progression from MCI to AD. Recent advances further support a notion that plasma A beta levels, expressed as an A beta 42/A beta 40 ratio, could also be of value. New potential biomarkers are emerging, and CSF or plasma marker profiles may eventually become part of the clinician's toolkit for accurate AD diagnosis and management. These biomarkers, along with clinical assessment, neuropsychological testing and neuroimaging could achieve a much higher diagnostic accuracy for AD and related disorders in the future. SN - 0304-4602 UR - https://www.unboundmedicine.com/medline/citation/18536828/Biomarkers_of_mild_cognitive_impairment_and_Alzheimer's_disease_ L2 - http://www.annals.edu.sg/pdf/37VolNo5May2008/V37N5p406.pdf DB - PRIME DP - Unbound Medicine ER -